Cover Image

Advances in Host-Directed Therapies Against Tuberculosis

This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective – thus calling for pathway/fa...

Full description

Corporate Author: SpringerLink (Online service)
Other Authors: Karakousis, Petros C. (Editor, http://id.loc.gov/vocabulary/relators/edt), Hafner, Richard. (Editor, http://id.loc.gov/vocabulary/relators/edt), Gennaro, Maria Laura. (Editor, http://id.loc.gov/vocabulary/relators/edt)
Language:English
Published: Cham : Springer International Publishing : Imprint: Springer, 2021.
Edition:1st ed. 2021.
Subjects:
Immunology.
Infectious diseases.
Pharmacotherapy.
Infectious Diseases.
Online Access:https://doi.org/10.1007/978-3-030-56905-1
Table of Contents:
  • Section 1: Introduction
  • Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis
  • Section 2: Targeting immunometabolism
  • Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism
  • Chapter 3:The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells
  • Chapter 4: HIF-1α as a potential therapeutic target for tuberculosis treatment
  • Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis
  • Section 3: Enhancing anti-mycobacterial mechanisms
  • Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis
  • Chapter 7: Metformin: a leading HDT candidate for TB
  • Chapter 8: Statins as host-directed therapy for tuberculosis
  • Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms
  • Section 4: Targeting immune cells
  • Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis
  • Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma
  • Chapter 12: Targeting suppressor T cells
  • Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis
  • Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis
  • Chapter 15: Mucosal-associated invariant and Vγ9Vδ2 T cells
  • Chapter 16: Airway epithelial cells.-Section 5: Preclinical models for assessing HDTs
  • Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies
  • Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis
  • Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis
  • Section 6: Clinical trials of HDTs and special considerations for study endpoints
  • Chapter 20:Clinical trials of TB-HDT candidates
  • Chapter 21:Outcomes for clinical trials of host-directed therapies for tuberculosis
  • Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis.

Similar Items